Cycad Group

Prelude is a company focused on enhancing cybersecurity through its innovative products and educational initiatives. Founded in 2017 and based in New York, it offers an autonomous red team tool as a desktop application that enables users to simulate attacks and defenses, facilitating continuous security testing and training. This tool helps organizations identify vulnerabilities in their systems, allowing them to proactively strengthen their defenses. Additionally, in 2018, Prelude established the Prelude Institute in Manchester, New Hampshire, aimed at addressing the skills gap in the cybersecurity workforce. The institute provides training for individuals transitioning from other careers, equipping them with the necessary skills to become security analysts in just six months. By combining advanced technology with targeted education, Prelude seeks to bolster cybersecurity capabilities and improve the earning potential of participants in the new labor market.

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.

NanoSteel is an advanced materials company specializing in the design and commercialization of patented steels with exceptional mechanical properties derived from their nano-scale microstructure. The Company's primary focus is proprietary alloys for use as sheet steel in automotive light-weighting applications. It has developed multiple generations of ferrous materials innovations including metallic coatings, additive manufacturing powders, and sheet steel protected by over 300 patents filed and granted worldwide. NanoSteel’s nanostructured steel designs are providing next-generation performance across a wide range of global industrial markets. The company alloys are proven in oil & gas, mining, cement, concrete, and power industries. The recent advanced high strength steel (AHSS) sheet material is poised to redefine how steel is used in the automotive industry.

ClarVista Medical is a developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing, ClarVista was spun out from Prospex Medical, a medical device incubator, to pursue the development of the HARMONI™ IOL. Between 2012 and 2014, the company developed the first generation HARMONI™ system, conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system, conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.

SOFIE brings that vision to life by increasing the adoption and application diversity of theranostics by removing the cost and complexity traditionally associated with the technology. With a full line of imaging and radiochemistry systems and a premier radiopharmacy network and contract manufacturing organization to supply novel agents for diagnosis and therapy, the company is dedicated to improving patient health.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.

SOFIE brings that vision to life by increasing the adoption and application diversity of theranostics by removing the cost and complexity traditionally associated with the technology. With a full line of imaging and radiochemistry systems and a premier radiopharmacy network and contract manufacturing organization to supply novel agents for diagnosis and therapy, the company is dedicated to improving patient health.

Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

The company is applying innovative science to improve the quality of eggs (oocytes) and increase the success of in vitro fertilization (IVF). OvaScience's proprietary technology, exclusively licensed from Harvard Medical School and Massachusetts General Hospital, enables the use of a women's own cellular energy to improve egg quality. OvaScience was co-founded by Richard Aldrich, Michelle Dipp, M.D., Ph.D., and Christoph Westphal M.D., Ph.D., of Longwood Founders Fund, along with fertility expert and Harvard Medical School Professor Jonathan Tilly, Ph.D. of Massachusetts General Hospital, and aging expert and Harvard Medical School Professor David Sinclair, Ph.D. The company is backed by leading life science investors Longwood Founders Fund and Bessemer Venture Partners. The company has assembled a world-class team of leading reproductive endocrinologists, embryologists, scientists and advisers to bring this technology to patients.

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.

Iosil Energy Corporation produces "high purity polysilicon," the essential raw material for solar cells. The Corporation was founded in 2007, with its R&D facilities located in the National Institute for Nanotechnology In Edmonton, Alberta. The company has demonstrated its ability to produce high-purity solar grade polysilicon from the waste material (or “kerf”) created by wafer sawing operations, saving costs.

NanoSteel is an advanced materials company specializing in the design and commercialization of patented steels with exceptional mechanical properties derived from their nano-scale microstructure. The Company's primary focus is proprietary alloys for use as sheet steel in automotive light-weighting applications. It has developed multiple generations of ferrous materials innovations including metallic coatings, additive manufacturing powders, and sheet steel protected by over 300 patents filed and granted worldwide. NanoSteel’s nanostructured steel designs are providing next-generation performance across a wide range of global industrial markets. The company alloys are proven in oil & gas, mining, cement, concrete, and power industries. The recent advanced high strength steel (AHSS) sheet material is poised to redefine how steel is used in the automotive industry.

Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

SOFIE brings that vision to life by increasing the adoption and application diversity of theranostics by removing the cost and complexity traditionally associated with the technology. With a full line of imaging and radiochemistry systems and a premier radiopharmacy network and contract manufacturing organization to supply novel agents for diagnosis and therapy, the company is dedicated to improving patient health.

The Solaria Corporation, a solar technology company, manufactures cells and modules for the optics and semiconductor industries. The company develops cell and module technologies that fit into the existing value-add chain. It uses a low-concentration solar PV multiplying technology that produces PV cells from silicon material.

Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

NanoSteel is an advanced materials company specializing in the design and commercialization of patented steels with exceptional mechanical properties derived from their nano-scale microstructure. The Company's primary focus is proprietary alloys for use as sheet steel in automotive light-weighting applications. It has developed multiple generations of ferrous materials innovations including metallic coatings, additive manufacturing powders, and sheet steel protected by over 300 patents filed and granted worldwide. NanoSteel’s nanostructured steel designs are providing next-generation performance across a wide range of global industrial markets. The company alloys are proven in oil & gas, mining, cement, concrete, and power industries. The recent advanced high strength steel (AHSS) sheet material is poised to redefine how steel is used in the automotive industry.

Alaunos Therapeutics is a biotechnology company employing a novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System® to turn on and off and precisely modulate gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. Multiple new INDs for new targets using similar technology are expected in 2014 and 2015. ZIOPHARM is also developing novel small molecules as potential cancer therapeutics.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

PsiloQuest develops and commercializes CMP polishing pads for the semiconductor industry.

Catalytic Solutions manufactures and distributes emissions control systems and catalytic products for commercial and industrial applications. It manufactures nanostructured catalysts at its main facility in Oxnard, California. The company’s products are most commonly applied to automobile, diesel engine, and energy markets. Catalytic Solutions has manufacturing facilities in Oxnard, California; Reno, Nevada; Thornhill, Canada; and Malmo, Sweden. Catalytic Solutions, Inc. operates as a subsidiary of Clean Diesel Technologies Inc.

Catalytic Solutions manufactures and distributes emissions control systems and catalytic products for commercial and industrial applications. It manufactures nanostructured catalysts at its main facility in Oxnard, California. The company’s products are most commonly applied to automobile, diesel engine, and energy markets. Catalytic Solutions has manufacturing facilities in Oxnard, California; Reno, Nevada; Thornhill, Canada; and Malmo, Sweden. Catalytic Solutions, Inc. operates as a subsidiary of Clean Diesel Technologies Inc.